RxDoctor Payments Data

Syed Hussaini, MD

Neurology · Sherman, TXNPI 1881880714

Payments from drug & device makers

$5,633in general payments, 2019–2025

Across 248 payments — averaging $22.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Livanova USA, Inc.$1K
  • UCB, Inc.$530
  • Abbott$437
  • AbbVie$366
  • Genentech USA, Inc.$289
  • Pfizer$200
  • plus $2K from 39 others

What the payments were for

  • Travel & lodging$1,42625%
  • Food & beverage$4,20775%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,633 in reported general payments places this provider in the 55th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$117,875
Medicare patients
247
Services billed
968

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$109,910
Emgality PenGalcanezumab-Gnlm52$53,833
BriviactBrivaracetam33$47,507
AptiomEslicarbazepine Acetate18$38,929
QuliptaAtogepant19$29,111
RytaryCarbidopa/Levodopa16$22,382
XcopriCenobamate14$16,148
UbrelvyUbrogepant12$15,261
FycompaPerampanel12$13,943
Memantine Hcl313$12,900
Lacosamide28$5,725
Oxcarbazepine45$4,125
Pregabalin93$4,091
Levetiracetam82$3,258
Entacapone31$2,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$83$109,91012 claims
UCB, Inc.Briviact$530$47,50733 claims
AbbVieQulipta, Ubrelvy$366$44,37231 claims
Sunovion Pharmaceuticals Inc.Aptiom$91$38,92918 claims
Amneal Pharmaceuticals LLCRytary$129$22,38216 claims
SK Life Science, Inc.Xcopri$137$16,14814 claims
Eisai Inc.Fycompa$16$13,94312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,246 neurology providers in Texas.

Other neurology in Sherman

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →